Mahta Mardani, MD, MPH

Washington University in St. Louis (WU)

Patients with metastatic breast cancer with bone metastasis as the only site of metastatic disease have lower survival outcomes for CDK4/6inhibitor therapy and immune therapy, we are trying to understand the mechanisms involved in bone met treatment resistance.